Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Cyclosporine on CHF6001 PK in Healthy Volunteers
NCT06892756Phase 1Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Mar 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tanimilast in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration at 96 hours and Maximum plasma concentration at 96 hours. Started Mar 2025; status: completed.
02
Drugs
tanimilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06892756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06892756.